ADVISORY BOARD

Jonathan Schatz, M.D.

Dr. Schatz is a physician-scientist at the University of Miami. Dr. Schatz’s work focuses on novel therapies for non-Hodgkin lymphomas. He treats patients affected by these diseases at the Sylvester Comprehensive Cancer Center (SCCC). Dr. Schatz also serves as the leader for the Development of Biologic and Molecular Therapies (DBMT) program at SCCC. Dr Schatz has expertise in murine lymphoma models, focusing on genetically accurate immunocompetent systems. He also employs genomic, biochemical, molecular biologic, and tissue culture techniques in understanding mechanisms of lymphomagenesis. 

Dr. Nassif is an artificial intelligence and machine learning scientist with background and expertise in the biomedical domain. He is an expert in computational modeling techniques, with over 15 years of algorithmic research and innovation. With a formal training and years of work and research in both the computer science and biomedical fields, Dr. Nassif has an extensive experience in inventing and applying machine learning algorithms for protein-binding modeling and breast cancer detection.

Houssam Nassif, Ph.D.

Dr. Campagna is currently Senior Vice President and Global NASH lead at Intercept Pharmaceuticals. He graduated from the combined MD/PhD program at The University of Miami in 1997 with a Ph.D. in Molecular and Cellular Pharmacology, and then completed his post-doctoral fellowship, Internal Medicine internship, Anesthesia and Critical Care residency, and Cardio-Thoracic Anesthesia fellowship all at the Massachusetts General Hospital in Boston. He is a board-certified critical care anesthesiologist.

Jason Campagna, M.D./Ph.D.

Rick Toren

Rick Toren, a serial healthcare entrepreneur, has an extensive history of success in the medical industry, both as a proven CEO and inventor. Throughout his career, Toren has worked to improve the efficiency of the medical industry by identifying needs and finding solutions. The first example of this came when Toren invented a product that provided users with the ability to treat life threatening allergic reactions - now known as the EpiPen. He has founded and managed multiple startups, which he directed to successful exits. Examples of this include ActiveHealth (acquired by Aetna for $400 million) and CodRyte (acquired by 3M for $150 million). Toren provides Truvitech with extensive industry knowledge and startup experience.